REFERENCES
  1. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249
  2. Kattan M. Statistical prediction models, artificial neural networks, and the sophism “I am a patient, not a statistic”. J Clin Oncol 2002; 20:885–7.
  3. D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969–974
  4. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173:1938–42
  5. Yoshioka Y, Inoue T. Prostate Risk Index (PRIX) as a new method of risk classification for clinically localized prostate cancer. Strahlenther Onkol 2007;183:490–6.
  6. Yoshida T, Nakayama M, Matsuzaki K Et al. Validation of the Prostate Cancer Risk Index (PRIX): A Simple Scoring System to Predict Risk of Biochemical Relapse after Radical Prostatectomy for Prostate Cancer Jpn J Clin Oncol 2011;41(11)1271–1276
  7. Soga N, Ogura Y, Wakita T, Kageyama T, Furusawa J The GP Score, a Simplified Formula (Bioptic Gleason Score Times Prostate Specific Antigen) as a Predictor for Biochemical Failure after Prostatectomy in Prostate Cancer Curr Urol 2019;13:25–30
  8. Lughezzani G, Budaus L, Isbarn H. et al. Head-to-Head Comparison of the Three Most Commonly Used Preoperative Models for Prediction of Biochemical Recurrence After Radical Prostatectomy Eur Urol 2010;57(4):562-8.
  9. Brierley JD, et al., TNM classification of malignant tumors. UICC International Union Against Cancer. 8th edn. 2017
  10. Meurs P, Galvin R, Fanning DM, Fahey T Prognostic value of the CAPRA clinical prediction rule: a systematic review and meta-analysis BJU Int 2013 Mar;111(3):427-36.
  11. Harrell Jr FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543–6.
  12. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361–87.
  13. Pak S, Lee DE, You D. et al. Validation of the European association of urology biochemical recurrence risk groups after radical prostatectomy in an Asian cohort and suggestions for refinement Urol Oncol 2021 Feb 9;S1078-1439(20)30653-0. doi: 10.1016/j.urolonc.2020.12.023.
  14. Tamblyn DJ, Chopra S, Yu C et al. Comparative analysis of three risk assessment tools in Australian patients with prostate cancer BJU Int 2011;108 (2):51-6.
  15. Mithal P, Howard LE, Aronson WJ et al. Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database Int J Urol 2015;22(4):362-6.
  16. Acimovic M, Stankovic KD, Pejcic T et al. Preoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy J BUON 2013;18(4):954-60
  17. Capogrosso P, Vertosick EA, Benfante NE et al. Can We Improve the Preoperative Prediction of Prostate Cancer Recurrence With Multiparametric MRI? Clin Genitourin Cancer 2019;17(4):e745-e750
  18. Manceau C, Beauval JB, Lesourd M et al. MRI Characteristics Accurately Predict Biochemical Recurrence after Radical Prostatectomy J Clin Med 2020 Nov 26;9(12):3841
  19. Remmers S, Verbeek JFM, Nieboer D, Kwast van der T, Roobol MJ Predicting biochemical recurrence and prostate cancer-specific mortality after radical prostatectomy: comparison of six prediction models in a cohort of patients with screening- and clinically detected prostate cancer BJU Int 2019;124(4):635-642